Thursday, 18 April 2024
Trending

[the_ad_group id="2845"]

Investing

Grifols Procleix ArboPlex Assay ® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus Screening By Investing.com

Benchmark Starts FingerMotion at Buy, Sees 73% Upside

[the_ad id="21475"]

[ad_1]

  • Grifols’ in vitro nucleic acid test detects four types of arboviruses, helping mitigate the risk of transfusion-transmitted infections
  • Arboviruses are a growing emerging threat, with changes in climate and increasing global connectivity making the geographic spread more prevalent
  • CE mark for Grifols’ Procleix ArboPlex Assay reinforces the company’s leadership in transfusion medicine and commitment to ensuring the safety of the world’s blood supply

BARCELONA, Spain, April 04, 2024 (GLOBE NEWSWIRE) — Grifols (MCE: GRF, MCE: GRF.P NASDAQ: GRFS), one of the world’s leading producers of plasma-derived medicines and innovative diagnostic solutions, today announced that its new Procleix ArboPlex Assay has obtained the CE mark under the In Vitro Diagnostic Regulation (IVDR), the first for an automated nucleic acid test (NAT) specifically validated for screening blood donors to detect four major arboviruses: chikungunya, dengue, West Nile and Zika viruses.

These are the four most significant arboviruses of concern, all spread through mosquito vectors. Changes in climate and increasing global connectivity have made the geographic spread of “ and growing exposure to “ arboviruses a major public health concern. With the dengue virus alone, there were more than 5 million cases and 5,000 deaths reported globally in 2023.1

Further strengthening the Grifols Procleix portfolio for blood donor screening, the Procleix ArboPlex Assay uses plasma or serum samples to detect arboviral RNA. Currently, risk for arboviruses in blood donors is evaluated either with a monoplex test, duplex test or through a questionnaire in which donors who declare having traveled to or prior residence in arbovirus-endemic areas are temporarily deferred. Blood banks and collection centers could decide that deferrals are unnecessary if donors were tested and found negative using the Procleix ArboPlex Assay.

With its 4-in-1 arbovirus test feature, the Grifols Procleix ArboPlex Assay has the ability to speed up and overall improve donor screening laboratory efficiency, said Antonio Martínez, president of Grifols Diagnostic Business Unit. Certification of this new assay provides a reliable and efficient solution to ensure accurate and consistent results, demonstrating Grifols’ continued commitment to innovating blood screening safety.

The Procleix ArboPlex Assay will be available in all markets accepting the CE mark certification after completion of any additional registration and…

Click Here to Read the Full Original Article at All News…

[ad_2]

[the_ad id="21476"]